cisplatin / Generic mfg. - LARVOL DELTA

Reframing Breast Cancer Therapies in a Rare Context - A Case of Metastatic Mammary-Like Vulvar Carcinoma Treated with Breast Cancer Regimens (SABCS 2025) - "She received adjuvant radiation with concurrent cisplatin. Given HER2 positivity, she was treated with six cycles of docetaxel, trastuzumab, and pertuzumab, followed by maintenance trastuzumab and pertuzumab...She was treated with olaparib from February to November 2023. Following disease progression, she transitioned to trastuzumab deruxtecan for HER2-low disease, which resulted in temporary disease control between December 2022 to May 2024. Upon further progression, she received carboplatin, paclitaxel, and bevacizumab, completing six cycles in May 2024, followed by maintenance bevacizumab and pembrolizumab... MLVA is an extremely rare malignancy with no established standards of care. Its histologic resemblance to breast cancer suggests it may respond to breast cancer-based therapies. In the absence of defined treatment pathways, applying breast cancer therapeutic strategies—particularly in the metastatic setting—may offer a rational and effective approach for managing..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • BRCA2 • ER • GATA3 • HER-2 • PAX8 • PGR • SOX10

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer (clinicaltrials.gov) - P2 | N=45 | Not yet recruiting | Sponsor: Tongji Hospital

New P2 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Exosomal SNHG26 mediates immunosuppression by impairing NK cells in tongue cancer. (PubMed, NPJ Precis Oncol) - "SNHG26 depletion reversed NK cell suppression and cisplatin resistance in vitro and in vivo. Thus, our study identifies exosomal SNHG26 as a key mediator of cisplatin resistance and NK cell dysfunction in TSCC, suggesting its potential as a promising therapeutic target."

Journal • Oncology • Oral Cancer • Squamous Cell Carcinoma • Targeted Protein Degradation • Tongue Carcinoma • HLA-DRA • IL2 • SOX2 • STAT5 • TGFB1 • WWP2

Induction serplulimab and cetuximab combined with chemotherapy followed by radiotherapy for unresectable locally advanced HNSCC: A single-arm, prospective, phase II study (ESMO Asia 2025) - "Patients received serplulimab (4.5 mg/kg, Q3W) + cetuximab (400 mg/m2 loading, followed by 250 mg/m2, QW) + liposomal paclitaxel (135 mg/m2, D1) + cisplatin (75 mg/m2, Q3W), for 3 weeks per cycle, with 2 total treatment cycles. In patients with unresectable LA-HNSCC, this induction regimen showed preliminary efficacy and manageable toxicity. Further follow-up is required to confirm the survival benefit."

Clinical • Metastases • P2 data • Head and Neck Cancer • Hypopharyngeal Cancer • Nasopharyngeal Carcinoma • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

The risk of symptomatic radiation pneumonitis in small cell lung cancer patients following sequential immunochemotherapy and radiotherapy: a multicenter retrospective cohort study. (PubMed, Radiat Oncol) - "The incidence of RP2 + following sequential immunochemotherapy and RT was positively associated with male and CCRT, but negatively correlated with VO2 max in SCLC patients."

Journal • Retrospective data • Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor

Visualizing Viscosity Changes in Tumor and Rheumatoid Arthritis with a Dual-Targeted NIR Fluorescent Probe. (PubMed, Anal Chem) - "Cellular imaging analysis showed that BHD can effectively detect apoptosis induced by hydrogen peroxide (H2O2) and cisplatin. By monitoring the variation in fluorescence intensity, BHD can efficiently monitor ferroptosis induced by erastin and further showed that Ferrostatin-1 (Fer-1) was able to inhibit this process. Notably, in vivo imaging of viscosity fluctuations associated with tumoral ferroptosis and rheumatoid arthritis (RA) models has been successfully accomplished."

Journal • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

Outcomes and recurrence pattern analysis of intensity modulated chemoradiotherapy in nasopharyngeal cancer: a retrospective study from Heidelberg University Hospital. (PubMed, Radiat Oncol) - "IMRT with weekly cisplatin yields excellent survival and locoregional control with acceptable toxicity in NPC. Distant metastasis as one of the predominant failure patterns highlights the need for more effective systemic therapies. Most local recurrences arose within high-dose areas, suggesting a potential opportunity for treatment optimization."

Journal • Retrospective data • Gastrointestinal Disorder • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Tumor-stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer. (PubMed, FEBS Open Bio) - "Gemcitabine/Cisplatin (Gem/Cis) chemotherapy is a standard treatment for muscle-invasive bladder cancer (MIBC) but yields suboptimal response rates. Using TCGA bladder cancer data, the transcriptomic gene set was further validated revealing a prognostic signature associated with patients' outcome. These findings uncover a novel mechanism of chemotherapy resistance in bladder cancer driven by tumor-stromal interactions and macrophage recruitment and suggest that targeting macrophage infiltration may improve chemotherapy response in bladder cancer."

IO biomarker • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CXCL1 • CXCL8 • PD-L1 • PD-L2 • SPP1

Uncovering functional divergence and cellular clusters with specific gene signatures in HNSCC clonal spheroids. (PubMed, Cell Commun Signal) - "Hyperproliferative spheroids (HRPS) showed increased proliferation and tumorigenic potential, whereas hypoproliferative spheroids (HOPS) demonstrated enhanced migration and resistance to cisplatin and radiation...Notably, the gene expression profiles of Cluster 3 in the HOPS and Cluster 1 in the HRPS closely matched the expression patterns observed in the HNSCC-TCGA dataset. These clusters also displayed a high transcriptional correlation between patient tumors and their xenografts, reinforcing the clonal nature of HNSCC's genetic and functional diversity of HNSCC."

Gene Signature • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ALDH3A1 • ANLN • AURKA • CKS2 • KRT15 • TOP2A

Inflammasome activation contributes to cisplatin resistance in ovarian cancer. (PubMed, J Ovarian Res) - "Our findings suggest that inflammasome activation and pyroptosis are mechanisms associated with ovarian cancer chemoresistance to CDDP, contributing to the devastating scenario of this disease. Targeting the NLRP1 and NLRP3 pathways could represent a promising strategy to improve OC treatment."

Journal • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • ANXA5 • IL1B • IL6 • NLRP1 • NLRP3 • TNFA

Nanotechnology-based approaches for head and neck cancer treatment. (PubMed, Biomed Pharmacother) - "In this review, we summarize the development of different DDS platforms encapsulating either cisplatin or small-molecule inhibitors, highlighting preclinical studies and clinical trials in HNSCC. A particular emphasis is placed on the distinction between passive and active targeting strategies, offering a comprehensive overview of how nanoparticle functionalization and tumor-selective delivery can further enhance therapeutic outcomes. This dual perspective underscores the translational opportunities of nanomedicine within the evolving landscape of HNSCC treatment."

Journal • Review • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Targeted Protein Degradation

Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms. (PubMed, Acta Biomater) - "NMIBC usually affects the mucosa and submucosa of the bladder tissue, requiring tumor resection, followed by intravesical administration of mitomycin-C. MIBC commonly affects the deeper layers of bladder, being associated with the origin of metastases, and it is recommended to perform a radical cystectomy followed by cisplatin-based neoadjuvant chemotherapy...Organoids, spheroids, and hydrogels are established drug screening tools. 3D models show strong potential for translation into clinical applications."

Journal • Preclinical • Review • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Celastrol synergizes with MEK1 inhibitor nedometinib to overcome resistance in bladder cancer via dual suppression of CDK1/CDC5L and feedback-activated Akt/STAT3. (PubMed, Biochem Pharmacol) - "Bladder cancer, particularly in its advanced and cisplatin-resistant forms, poses a significant clinical challenge due to limited therapeutic options...Our results indicate that CST dually inhibits CDK1 and CDC5L and synergizes with the MEK1 inhibitor by suppressing feedback-driven resistance pathways. These findings support the CST + NB combination as a novel multi-target therapeutic strategy with potent activity against bladder cancer and rectal adenocarcinoma."

Journal • Bladder Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Genito-urinary Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • CDK1 • PTEN • STAT3

Collision-induced ribosome degradation driven by ribosome competition and translational perturbations. (PubMed, Nat Commun) - "We further show that endogenous ribosomal subunit stoichiometry shifts toward a small-subunit-shortage state via ubiquitination upon perturbed translation triggered by the anti-cancer drug cisplatin and the growth phase transition. These findings reveal a mechanism by which ribosome dynamics generally affects ribosome stability, implicating ribosome dysfunction, heterogeneity, and stress-related translational disturbances in small subunit degradation."

Journal • Oncology • Targeted Protein Degradation

REVIVE: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: AstraZeneca

Biomarker • New P4 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Tumor-infiltrating lymphocyte therapy in lung cancer: A systematic review (ASH 2025) - "TILs were sourced from lung or metastatic sites, expanded ex vivo, and administered following lymphodepletion (primarily cyclophosphamide/fludarabine)...Median OS was 22.4 months in the TIL group, compared to 14.1 months with cisplatin (Ratto et al.) and 371.8 days in another TIL cohort (Chu et al.)... TIL therapy shows encouraging clinical activity and manageable toxicity in lung cancer, with improvements in survival, response rates, and quality of life. However, small sample sizes and study variability limit definitive conclusions. Larger, standardized trials are needed to confirm its long-term benefits."

IO biomarker • Review • Tumor-infiltrating lymphocyte • Febrile Neutropenia • Hypotension • Lung Cancer • Melanoma • Neutropenia • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • PD-L1

Isa-PACE in the treatment of functionally high-risk multiple myeloma: Intermediate results. (ASH 2025) - "In the absence of chimeric antigen receptor T-cell (CAR-T) therapy in Russia, the Isa-PACE (isatuximab + cisplatin, doxorubicin, cyclophosphamide, and etoposide) combination is considered a potential bridge therapy to auto-HSCT...All patients continue to receive maintenance therapy with isatuximab and lenalidomide, while maintaining MRD-negative status...Intermediate assessment of PET/CT imaging effectively reflected the response to treatment and identified the need for treatment intensification. Expanding the sample size will help to clarify the prognostic significance of this approach and aid in stratifying patients with NDMM."

Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Human Papillomavirus Infection • Infectious Disease • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia

Outcomes of infusional chemotherapy regimens in multiple myeloma: A retrospective review at a single center from 2018 to 2025 (ASH 2025) - "Despite emergence of novel agents, the use of traditional multi-agent infusional regimens such as DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin) and V(T)D-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) remain critical in select clinical scenarios. These regimens continue to be valuable in providing rapid cytoreduction or as a bridge to definitive therapy. Larger sample sizes are required in order to perform statistical analysis on subgroups to better characterize differences in therapy with respect to progression free survival, overall response rate, and time to response."

Retrospective data • Review • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

High transplant conversion rates with gemcitabine, dexamethasone and carboplatin (GDP)-based therapy in Relapsed/Refractory lymphoma: A real-world experience (ASH 2025) - "G-CSF and Plerixafor-mobilized peripheral blood stem cell were used in all patients...Eligible patients received agents like Rituximab, Brentuximab, and Nivolumab with additional cost per cycle...The regimen's daycare feasibility and reduced hospitalization needs offer significant quality-of-life and economic advantages. Substituting Carboplatin for Cisplatin further enhances administration convenience."

Clinical • Real-world • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Transplantation

Experience with prolgolimab in the treatment of patients with relapsed and refractory classical Hodgkin lymphoma (ASH 2025) - "Objective: To evaluate the efficacy and safety of prolgolimab both as monotherapy and in combination with DHAP chemotherapy (dexamethasone, cytarabine, cisplatin), as well as to assess the feasibility of peripheral blood stem cell (PBSC) collection followed by auto-HSCT in patients with r/r cHL...Disease progression was noted in 6 patients, who were subsequently switched to bendamustine-based chemotherapy regimens. PBSC collection was successfully performed in 15 patients after chemomobilization with etoposide (375 mg/m²/day on days 1–2)... The combination of prolgolimab with DHAP chemotherapy is highly effective and safe, with no negative impact on PBSC collection. Achieving tumor response prior to auto-HSCT and the use of prolgolimab as consolidation therapy can lead to durable remissions without additional toxicity in patients with r/r cHL."

Clinical • Bone Marrow Transplantation • Cardiovascular • Classical Hodgkin Lymphoma • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Pulmonary Embolism • Respiratory Diseases • CD34 • PD-L2

Real-world outcomes of Mantle Cell Lymphoma in Colombia: A multicenter cohort study (ASH 2025) - "The most common induction regimens were cytarabine-based, including Rituximab - cyclophosphamide - doxorrubicin - vincristin - prednisolone (R-CHOP)/ Rituximab - dexamethasone - citarabine - cisplatin (R-DHAP) (LYMA) (46.2%, n = 37) followed by the Nordic regimen (12%, n = 10) and Bendamustine-Rituximab (BR)(10.0%, n = 8). Other treatment regimens were R-CHOP/R-miniCHOP (10.0%, n = 8), and rituximab - bendamustine - cytarabine (R-BAC) (8.8%, n = 7)...Of 39 receiving second-line therapy, 31 (44%) were treated with BTK inhibitor ibrutinib, which remains approved only for relapsed/refractory disease in Colombia... Our 5-year overall survival (OS) rate of 66.2% exceeded the 57.1% reported in a broader Latin American cohort (Pavlovsky et al., 2022), suggesting potential regional differences in outcomes. Despite the established survival benefit of autologous stem cell transplantation (ASCT), over one-third of eligible patients did not undergo transplant, highlighting ongoing..."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • MYC • SOX11 • TP53

Establishment of a prognostic model for diffuse large B-cell lymphoma based on mitochondrial energy metabolism-related genes (ASH 2025) - "Drug sensitivity prediction further revealed that high-risk patients may respond better to cisplatin and oxaliplatin but show reduced sensitivity to venetoclax. In summary, this study established a novel MMRG-based prognostic model that enables precise risk stratification and reveals key links between mitochondrial metabolism and the immune landscape in DLBCL. These findings provide valuable insights for individualized prognosis evaluation and the development of metabolism-immune targeted therapies."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • ACSL5 • ADH1A • ASXL1 • CPT1A • DOT1L • MCL1 • PLK1

Molecular pathology of testicular germ cell tumours: an update for practicing pathologists. (PubMed, Histopathology) - "Alterations associated with the formation of a somatic-type malignancy and/or the development of cisplatin resistance include TP53 mutations or MDM2 gene amplifications as well as epigenetic alterations...Additionally, we will provide guidance on how to examine a testicular tumour specimen histopathologically to reach an accurate diagnosis. Finally, we will outline the importance of the content of a histopathological report for the urologists and oncologists."

Biomarker • Journal • Review • Embryonal Tumor • Germ Cell Tumors • Oncology • Testicular Cancer • Testicular Seminoma • AFP • BRAF • DMRT1 • KIT • KRAS • MDM2 • TP53

Four new dammarane nortriterpenoids isolated from mastic (Pistacia lentiscus L.) and their anti-inflammatory and cytotoxic activities. (PubMed, Nat Prod Res) - "Compounds 5-8 showed certain inhibitory NO production in LPS-induced RAW264.7 cells with IC50 values of 24.84-37.15 μM (positive control dexamethasone, 11.27 ± 2.25 μM). Compound 7 significantly inhibited the growth of SW480 cells, with an IC50 value of 30.76 ± 2.75 μM, comparable to that of the positive control cisplatin (25.91 ± 1.44 μM). Additionally, the effects of all the compounds on HCT116 cells were not significant."

Journal